Global Iron Deficiency Anemia Therapy Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 4.86 Billion |
 Taille du marché (année de prévision) |
USD 10.08 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial des thérapies contre l’anémie ferriprive, par thérapie (thérapie parentérale au fer et thérapie orale au fer), domaine thérapeutique (obstétrique et gynécologie, maladies rénales, insuffisance cardiaque congestive (ICC), oncologie , maladies inflammatoires de l’intestin et autres), population (adultes, gériatrie et pédiatrie), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (pharmacie hospitalière, pharmacies et pharmacies de détail et pharmacies en ligne) – Tendances et prévisions de l’industrie jusqu’en 2031.
Analyse et taille du marché du traitement de l'anémie ferriprive
Le marché mondial des traitements contre l' anémie ferriprive connaît une croissance significative, tirée par l'augmentation des cas d'anémie ferriprive, l'introduction de nouveaux médicaments sur le marché et l'orientation vers les soins de santé sociaux pour la santé des femmes, en particulier l'anémie. Le marché est caractérisé par la présence d'un grand nombre d'acteurs proposant une large gamme de thérapies adaptées aux divers besoins des prestataires de soins de santé de la région.
Data Bridge Market Research analyse que le marché mondial du traitement de l'anémie ferriprive devrait atteindre 10,08 milliards USD d'ici 2031, contre 4,86 milliards USD en 2023, avec un TCAC de 10,0 % au cours de la période de prévision de 2024 à 2031. L'augmentation de l'incidence de l'anémie ferriprive devrait stimuler l'expansion du marché.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Année historique |
2022 (Personnalisable 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en milliards USD |
|
Segments couverts |
Thérapie (thérapie parentérale au fer et thérapie orale au fer), domaine thérapeutique (obstétrique et gynécologie, maladies rénales , insuffisance cardiaque congestive (ICC) , oncologie, maladies inflammatoires chroniques de l'intestin et autres), population (adultes, gériatrie et pédiatrie), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (pharmacie hospitalière, pharmacies et pharmacies de détail et pharmacies en ligne) |
|
Pays couverts |
Mexique, Canada, États-Unis, Royaume-Uni, Allemagne, Italie, France, Espagne, Belgique, Suisse, Turquie, Russie, Pays-Bas, Reste de l'Europe, Inde, Chine, Japon, Australie, Thaïlande, Malaisie, Corée du Sud, Philippines, Singapour, Indonésie, Reste de l'Asie-Pacifique, Argentine, Brésil, Reste de l'Amérique du Sud, Afrique du Sud, Égypte, Arabie saoudite, Émirats arabes unis, Israël, Reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Vifor Pharma Ltd., DAIICHI SANKYO COMPANY, LIMITED, AFT Pharmaceuticals., Sanofi, Pfizer Inc., Fresenius Kabi AG, PHARMACOSMOS Therapeutics Inc, Thorne, Lupin, BLACKMORES, Shield Therapeutics plc, Aspen Pharmacare Australia Pty Ltd. Soins de santé, entre autres. |
Définition du marché
Iron deficiency anemia therapy is a treatment approach aimed at replenishing iron stores and correcting anemia caused by iron deficiency. The primary goal of therapy is to restore normal iron levels and hemoglobin production, thereby improving symptoms such as fatigue, weakness, and shortness of breath. Therapy typically involves oral iron supplementation, which can be in the form of ferrous sulfate, ferrous gluconate, or ferric citrate, and may be administered alone or in combination with other medications to enhance absorption and efficacy. In severe cases, intravenous iron therapy may be necessary, and in some instances, blood transfusions may be required to rapidly increase hemoglobin levels.
Global Iron-Deficiency Anemia Therapy Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Incidences of Iron Deficiency Anemia
Anemia is defined as a low concentration of blood hemoglobin. It is a health problem that affects all economical sections of world ranging from low-, middle- and high-income countries. Significant adverse health consequences of anemia along with worse impacts on economic and social development.
Anemia occurs due to various etiologies, with the most common contributor is iron deficiency. Approximately 50% of cases of anemia cases are caused due to iron deficiency, but the ratio probably varies due to various factors.
Other causes of anemia include other deficiencies of micronutrient (e.g. vitamins A, folate, riboflavin and B12), chronic and acute infections (e.g. cancer, tuberculosis, malaria, and HIV), and acquired or inherited disorders that affect synthesis of hemoglobin, red blood cell (RBC) production or survival.
Iron deficiency anemia is said to be the most common form of anemia found globally. In this condition, blood lacks sufficient healthy red blood cells (RBC’s) which functions to carry oxygen to the tissue of the body’s Iron deficiency anemia is caused due to insufficient iron.
The lack of proper nutrition and various inflammations in body, which renders the poor absorption of the iron, leads to increased prevalence of iron deficiency anemia.
For instance,
- According to a report by India Spend, published in 2016, 20% of maternal deaths in India were caused by anemia and was the associate cause in 50% of maternal deaths in October 2016. Low birth weight among babies and risking them for lifelong issues involving physical growth and cognitive development is caused by anemia. According to statistics, the efficiency of anemic children reduces to 2.5% as adults compared to their healthier peers.
- According to Global Nutrition Report 2017, it reported that just over half (51%) of women of reproductive age (15 to 49 years) are anemic in India and according to the report in the fourth National Family Health Survey (NFHS-IV) in 2015-16 it is estimated that 53% of the women were anemic in India in the reproductive age
Introduction of Novel Drugs in the Market
Innovation drives progress, the availability of novel drugs, lead products and biological products often means new hope and better treatment options for patients and advancement in health care for public worldwide. Some of the products are new and innovative with novel approach that have never been used in clinical practice and have potential benefits to cure the persisting ailment in the population worldwide. The various drugs and therapies are made with advanced research and development and thorough testing using subjects to check their efficiency.
For instance,
- In December 2023, according to an article published by FDA, the U.S. FDA approved two landmark treatments, Casgevy and Lyfgenia, as the first cell-based gene therapies for sickle cell disease (SCD) in patients 12 years and older. Notably, Casgevy is the first FDA-approved treatment to use novel genome editing technology, marking a significant advancement in gene therapy
- These breakthroughs will drive the global iron-deficiency anemia therapy market by highlighting the potential for innovative treatments and encouraging further research and development in anemia-related therapies
- In September 2023, according to an article published by GSK plc., GSK plc. announced FDA approval of Ojjaara (momelotinib) for treating intermediate or high-risk myelofibrosis, including primary and secondary myelofibrosis, in adults with anemia. Ojjaara, a once-daily oral JAK1/JAK2 and ACVR1 inhibitor, is the only approved treatment for both newly diagnosed and previously treated myelofibrosis patients with anemia, addressing anemia, constitutional symptoms, and splenomegaly.
Opportunity
- Increasing Research and Development Activities
Herbs, fungi and plants for curing anemia have been used in medicinal traditions indigenous for millennia. The increased prevalence of anemia worldwide is causing a social problem in the world leading to more rigorous research and development need in the respected field. After decades of persistent advocacy and education, rigorous research and development employing iron deficiency anemia as tools of healing and discovery are abundant.
Currently, various research studies are taking place in private practice sites and in research institutions supported by for-profit and non-profit organizations, along with individual research studies. This research includes clinical trials for intravenous therapy for the treatment of iron deficiency anemia associated with chronic heart disease, chronic kidney diseases dependent on dialysis or non-dependent of dialysis.
For instance,
- En mars 2022, selon un article publié par le National Heart, Lung, and Blood Institute, les chercheurs du NHLBI ont contribué au traitement de l'anémie aplasique, une maladie rare dans laquelle la moelle osseuse ne produit pas suffisamment de cellules sanguines. Ils ont développé des médicaments immunosuppresseurs pour gérer ce trouble. Les recherches financées par le NHLBI continuent d'explorer les causes de l'anémie, en étudiant la production de globules rouges chez les personnes en bonne santé et celles souffrant d'anémie. De plus, le NHLBI et le NCI ont lancé le Blood and Marrow Transplant Clinical Trials Network en 2001 pour faire progresser les thérapies de transplantation, guérissant potentiellement certains types d'anémie
- Ces efforts offrent des opportunités pour le marché mondial du traitement de l’anémie ferriprive en favorisant l’innovation dans les approches thérapeutiques, y compris les thérapies génétiques, et en soutenant les essais cliniques qui pourraient conduire à de nouveaux traitements efficaces contre l’anémie dans le monde entier.
Retenue/Défi
- Limites du diagnostic de l'anémie ferriprive dans les maladies inflammatoires
L'anémie ferriprive est un problème de santé majeur dans le monde entier. Elle représente l'une des maladies non mortelles les plus répandues dans le monde et est fréquemment observée dans la pratique clinique ordinaire. Un pronostic et un diagnostic rapides sont essentiels en raison du rôle important joué par le fer dans le fonctionnement de tous les systèmes organiques. Malgré sa prévalence, la carence en fer est généralement négligée chez les patients atteints de maladies inflammatoires, principalement en raison du mélange de symptômes et de définitions fournis dans les directives de préparation clinique.
Les groupes à risque les plus connus pour la carence en fer sont les personnes souffrant de malnutrition, celles qui ont besoin d'apports élevés en fer, comme les adolescents ou les femmes enceintes, et les personnes souffrant de pertes sanguines chroniques, par exemple en raison d'hémorragies gastro-intestinales ou d'une utérus abondant. L'attention se porte désormais de plus en plus sur le statut en fer des patients associés à des états inflammatoires qui les prédisposent à la carence en fer.
Les plus fréquentes sont l'insuffisance rénale chronique (IRC), l'insuffisance cardiaque chronique (ICC) et les maladies inflammatoires chroniques de l'intestin (MICI). L'estimation de la carence en fer chez les patients atteints de maladies inflammatoires est la moins bien diagnostiquée en raison du manque de mesures ou de marqueurs diagnostiques.
Par exemple,
- En juillet 2022, selon un article publié par PubMed Central, le diagnostic et le traitement de l’anémie ferriprive (IDA) reposent sur une détection précise de la carence en fer, qui est compliquée par des facteurs tels que l’inflammation, le régime alimentaire et les variations métaboliques. Les biomarqueurs actuels tels que l’hémoglobine (Hb), la ferritine sérique et les niveaux de saturation de la transferrine sont affectés par ces facteurs, ce qui les rend peu fiables dans certaines conditions. Par exemple, les niveaux de ferritine peuvent augmenter pendant l’inflammation, masquant les véritables niveaux de fer. L’utilisation de plusieurs marqueurs comme l’indice sTfR-F semble prometteuse pour surmonter ces défis, mais il reste nécessaire de disposer d’outils de diagnostic plus robustes
- Cette complexité diagnostique pose un défi important pour le marché mondial du traitement de l'anémie ferriprive, nécessitant le développement de méthodes de diagnostic plus précises et plus sensibles, capables d'identifier et de surveiller de manière fiable le statut en fer dans diverses populations de patients, y compris celles souffrant de maladies inflammatoires sous-jacentes ou de troubles génétiques spécifiques comme la drépanocytose.
- En 2018, selon un rapport publié dans la revue internationale des maladies chroniques par le département de médecine de l'hôpital Agaplesion Markus de l'université Goethe, en Allemagne, et le centre interdisciplinaire de la colite de Crohn de Rhin-Main, en Allemagne. Les estimations de la carence en fer dans les groupes de personnes atteintes de maladies inflammatoires ont beaucoup changé entre les études en raison de définitions contradictoires et de divers critères d'assortiment de patients. Ils ont constaté qu'environ 24 à 85 % des patients atteints d'IRC, 50 % des patients atteints d'ICC et 45 % des patients atteints de MII présentent une carence en fer
Développements récents
- En juin 2023, GSK a reçu un avis positif du Comité des médicaments à usage humain (CHMP), recommandant l'autorisation du daprodustat pour le traitement de l'anémie symptomatique associée à l'insuffisance rénale chronique (IRC) chez les adultes soumis à une dialyse d'entretien chronique. Cette recommandation marque une étape importante vers la mise à disposition d'une nouvelle option thérapeutique pour la prise en charge de l'anémie chez les patients atteints d'IRC sous dialyse à long terme, répondant ainsi à un besoin médical important non satisfait dans cette population
- En mars 2024, Vafseo a été approuvé par la FDA américaine pour le traitement de l'anémie due à une maladie rénale chronique chez les patients adultes dépendants de la dialyse. CSL Vifor est heureux que son partenaire Akebia Therapeutics, Inc. ait annoncé que la Food and Drug Administration (FDA) américaine a approuvé les comprimés de Vafseo (vadadustat) pour le traitement de l'anémie due à une maladie rénale chronique (MRC) chez les adultes sous dialyse depuis au moins trois mois. Vafseo est un inhibiteur oral du facteur prolyl hydroxylase inductible par l'hypoxie (HIF-PHI) développé par Akebia
- En février 2024, Lupin a lancé un spray nasal à base de cyanocobalamine, 500 mcg/spray (un spray par appareil), après avoir reçu l'approbation de la Food and Drug Administration des États-Unis (US FDA)
- En décembre 2023, Novartis a reçu l'approbation de la FDA pour Fabhalta (iptacopan), offrant une amélioration supérieure de l'hémoglobine en l'absence de transfusions en tant que première monothérapie orale pour les adultes atteints d'HPN. a annoncé que la Food and Drug Administration (FDA) américaine a approuvé Fabhalta (iptacopan) comme première monothérapie orale pour le traitement des adultes atteints d'hémoglobinurie paroxystique nocturne (HPN). Fabhalta est un inhibiteur du facteur B qui agit de manière proximale dans la voie alternative du complément du système immunitaire, offrant un contrôle complet de la destruction des globules rouges (GR) à l'intérieur et à l'extérieur des vaisseaux sanguins (hémolyse intra- et extravasculaire [IVH et EVH])
- En mars 2024, Santé Canada a approuvé Ferinject pour le traitement de l'anémie ferriprive chez les patients adultes et pédiatriques et de la carence en fer chez les patients adultes atteints d'insuffisance cardiaque. Santé Canada a annoncé que Santé Canada a autorisé Ferinject (carboxymaltose ferrique) pour le traitement intraveineux (IV) de l'anémie ferriprive chez les patients adultes et pédiatriques âgés d'un an et plus lorsque les préparations orales de fer ne sont pas tolérées ou sont inefficaces, ainsi que pour le traitement de la carence en fer chez les patients adultes atteints d'insuffisance cardiaque.
Portée du marché mondial des thérapies contre l'anémie ferriprive
Le marché mondial du traitement de l'anémie ferriprive est segmenté en cinq segments notables en fonction du traitement, du domaine thérapeutique, de la population, de l'utilisateur final et du canal de distribution. La croissance de ces segments vous aidera à analyser les principaux segments de croissance des industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour prendre des décisions stratégiques afin d'identifier les principales applications du marché.
Thérapie
- Thérapie parentérale au fer
- Thérapie orale au fer
Sur la base de la thérapie, le marché est segmenté en thérapie au fer parentéral et thérapie au fer oral.
Espace Thérapie
- Obstétrique et gynécologie
- Maladies rénales
- Insuffisance cardiaque congestive (ICC)
- Oncologie
- Maladie inflammatoire chronique de l'intestin
- Autres
Sur la base du domaine thérapeutique, le marché est segmenté en obstétrique et gynécologie, maladies rénales, insuffisance cardiaque congestive (ICC), oncologie, maladies inflammatoires de l'intestin et autres.
Population
- Adultes
- Gériatrie
- Pédiatrique
Sur la base de la population, le marché est segmenté en adultes, gériatriques et pédiatriques.
Utilisateur final
- Hôpitaux
- Cliniques spécialisées
- Cadre de soins à domicile
- Autres
Sur la base de l’utilisateur final, le marché est segmenté en hôpitaux, cliniques spécialisées, soins à domicile et autres.
Canal de distribution
- Pharmacie de l'hôpital
- Pharmacies et magasins de droguerie
- Pharmacies en ligne
Sur la base du canal de distribution, le marché est segmenté en pharmacie hospitalière, pharmacies , pharmacies de détail et pharmacies en ligne.
Analyse/perspectives régionales du marché mondial des thérapies contre l'anémie ferriprive
Le marché mondial de la thérapie de l’anémie ferriprive est analysé et des informations et tendances sur la taille du marché sont fournies en fonction de la thérapie, du domaine thérapeutique, de la population, de l’utilisateur final et du canal de distribution comme référencé ci-dessus.
Les pays couverts dans ce rapport de marché sont le Mexique, le Canada, les États-Unis, le Royaume-Uni, l'Allemagne, l'Italie, la France, l'Espagne, la Belgique, la Suisse, la Turquie, la Russie, les Pays-Bas, le reste de l'Europe, l'Inde, la Chine, le Japon, l'Australie, la Thaïlande, la Malaisie, la Corée du Sud, les Philippines, Singapour, l'Indonésie, le reste de l'Asie-Pacifique, l'Argentine, le Brésil, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Égypte, l'Arabie saoudite, les Émirats arabes unis, Israël, le reste du Moyen-Orient et de l'Afrique.
L'Amérique du Nord devrait dominer le marché mondial du traitement de l'anémie ferriprive en raison de son infrastructure de soins de santé avancée. Les États-Unis devraient dominer la région Amérique du Nord en raison de la prévalence élevée de la maladie, de politiques de remboursement solides et d'investissements importants dans la recherche et le développement. Le Royaume-Uni devrait dominer la région Europe en raison de la propension du gouvernement à privilégier les soins de santé sociaux pour la santé des femmes, en particulier l'anémie. L'Inde devrait dominer le marché du traitement de l'anémie ferriprive en Asie-Pacifique.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché mondiales du traitement de l'anémie ferriprive
Le paysage concurrentiel du marché mondial des thérapies contre l'anémie ferriprive fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché mondial des thérapies contre l'anémie ferriprive.
Certains des principaux acteurs opérant sur le marché mondial du traitement de l'anémie ferriprive sont Vifor Pharma Ltd., Daiichi Sankyo Company, Limited, AFT Pharmaceuticals., Sanofi, Pfizer Inc., Fresenius Kabi AG, Pharmacosmos Therapeutics Inc, Thorne, Lupin, Blackmores, Shield Therapeutics plc, Aspen Pharmacare Australia Pty Ltd. Health Care entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCES OF IRON DEFICIENCY ANEMIA
5.1.2 INTRODUCTION OF NOVEL DRUGS IN THE MARKET
5.1.3 INCLINATION TOWARDS SOCIAL HEALTHCARE ON WOMEN HEALTH SPECIFICALLY ANEMIA
5.2 RESTRAINTS
5.2.1 STRINGENT REGULATIONS FOR IRON DEFICIENCY ANEMIA THERAPY
5.2.2 AVAILABILITY OF ALTERNATIVE TREATMENT OPTIONS
5.2.3 HIGH COST OF THERAPY
5.3 OPPORTUNITIES
5.3.1 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
5.3.2 ENHANCING DRUG QUALITY AND REIMBURSEMENT POLICIES
5.3.3 STRATEGIC ACQUISITIONS AND MERGERS
5.4 CHALLENGES
5.4.1 LIMITATION IN DIAGNOSING IRON DEFICIENCY ANEMIA IN INFLAMMATORY CONDITIONS
5.4.2 EMERGING DRUG RESISTANCE
6 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY
6.1 OVERVIEW
6.2 PARENTERAL IRON THERAPY
6.3 ORAL IRON THERAPY
7 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA
7.1 OVERVIEW
7.2 OBSTETRICS AND GYNECOLOGY
7.3 RENAL DISEASES
7.4 CONGESTIVE HEART FAILURE (CHF)
7.5 ONCOLOGY
7.6 INFLAMMATORY BOWEL DISEASE
7.7 OTHERS
8 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION
8.1 OVERVIEW
8.2 ADULTS
8.3 GERIATRIC
8.4 PEDIATRIC
9 GLOBAL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME CARE SETTING
9.5 OTHERS
10 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 DRUG STORES AND RETAIL PHARMACIES
10.4 ONLINE PHARMACIES
11 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 MEXICO
11.2.2 CANADA
11.2.3 U.S.
11.3 EUROPE
11.3.1 U.K.
11.3.2 GERMANY
11.3.3 ITALY
11.3.4 FRANCE
11.3.5 SPAIN
11.3.6 BELGIUM
11.3.7 SWITZERLAND
11.3.8 TURKEY
11.3.9 RUSSIA
11.3.10 NETHERLANDS
11.3.11 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 INDIA
11.4.2 CHINA
11.4.3 JAPAN
11.4.4 AUSTRALIA
11.4.5 MALAYSIA
11.4.6 SOUTH KOREA
11.4.7 PHILIPPINES
11.4.8 SINGAPORE
11.4.9 INDONESIA
11.4.10 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 ARGENTINA
11.5.2 BRAZIL
11.5.3 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SOUTH AFRICA
11.6.2 EGYPT
11.6.3 SAUDI ARABIA
11.6.4 U.A.E.
11.6.5 ISRAEL
11.6.6 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 VIFOR PHARMA LTD.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 DAIICHI SANKYO COMPANY, LIMITED.
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT/ SERVICE PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 AFT PHARMACEUTICALS
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT/ SERVICE PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 PFIZER INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AKEBIA THERAPEUTICS, INC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ALKEM.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ASPEN PHARMACARE AUSTRALIA PTY LTD.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT/ SERVICE PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BLACKMORES
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT/ SERVICE PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 FARLEX
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 FRESENIUS KABI AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 GLAXOSMITHKLINE PLC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.13 LUPIN
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.14 NOVARTIS AG
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ORION CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 PHARMACOSMOS A/S
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SHIELD THERAPEUTICS PLC
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 COTHORNE
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT/ SERVICE PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 VIATRIS INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 PREVALENCE OF ANEMIA IN CHILDREN OF AFRICA AND ASIA
TABLE 2 IRON DEFICIENCY ANEMIA THERAPEUTICS R&D ACTIVITIES
TABLE 3 CAUSES, PREVALENCE, AND CLINICAL CONSEQUENCES OF IRON DEFICIENCY IN INFLAMMATORY CONDITIONS
TABLE 4 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL OBSTETRICS AND GYNECOLOGY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL RENAL DISEASES IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL CONGESTIVE HEART FAILURE (CHF) IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL ONCOLOGY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL INFLAMMATORY BOWEL DISEASE IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL OTHERS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 17 GLOBAL ADULTS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 GLOBAL GERIATRIC IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 GLOBAL PEDIATRIC IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 21 GLOBAL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 GLOBAL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 23 GLOBAL SPECIALTY CLINICS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 GLOBAL HOME CARE SETTING IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 27 GLOBAL HOSPITAL PHARMACY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 GLOBAL DRUG STORES AND RETAIL PHARMACIES IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 GLOBAL ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 40 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 41 MEXICO PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 MEXICO ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 44 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 45 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 46 MEXICO HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 47 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 48 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 49 CANADA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 CANADA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 51 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 52 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 53 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 54 CANADA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 55 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 56 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 57 U.S. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 U.S. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 60 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 61 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 U.S. HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 65 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 66 EUROPE PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 EUROPE ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 69 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 70 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 71 EUROPE HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 72 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 73 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 74 U.K. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.K. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 77 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 78 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 U.K. HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 82 GERMANY PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 GERMANY ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 85 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 86 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 87 GERMANY HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 88 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 89 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 90 ITALY PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 ITALY ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 93 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 94 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 ITALY HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 96 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 98 FRANCE PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 FRANCE ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 101 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 102 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 103 FRANCE HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 104 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 105 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 106 SPAIN PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 107 SPAIN ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 109 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 110 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 SPAIN HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 112 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 113 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 114 BELGIUM PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 BELGIUM ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 117 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 118 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 BELGIUM HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 120 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 121 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 122 SWITZERLAND PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 SWITZERLAND ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 125 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 126 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 127 SWITZERLAND HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 128 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 129 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 130 TURKEY PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 TURKEY ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 133 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 134 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 135 TURKEY HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 136 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 137 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 138 RUSSIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 RUSSIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 141 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 142 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 143 RUSSIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 144 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 145 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 146 NETHERLANDS PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 147 NETHERLANDS ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 149 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 150 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 151 NETHERLANDS HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 EREST OF EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 154 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 155 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 156 ASIA-PACIFIC PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 ASIA-PACIFIC ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 159 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 160 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 161 ASIA-PACIFIC HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 162 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 163 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 164 INDIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 INDIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 167 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 168 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 169 INDIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 172 CHINA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 CHINA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 175 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 176 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 CHINA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 178 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 179 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 180 JAPAN PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 JAPAN ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 182 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 183 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 184 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 185 JAPAN HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 186 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 187 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 188 AUSTRALIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 AUSTRALIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 191 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 192 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 193 AUSTRALIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 194 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 196 THAILAND PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 THAILAND ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 199 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 200 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 201 THAILAND HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 202 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 203 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 204 MALAYSIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 MALAYSIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 207 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 208 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 209 MALAYSIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 210 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 211 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 212 SOUTH KOREA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 213 SOUTH KOREA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 215 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 216 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 217 SOUTH KOREA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 218 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 220 PHILIPPINES PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 PHILIPPINES ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 224 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 225 PHILIPPINES HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 227 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 228 SINGAPORE PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 SINGAPORE ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 231 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 232 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 233 SINGAPORE HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 234 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 235 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 236 INDONESIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 INDONESIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 239 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 240 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 241 INDONESIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 242 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 243 REST OF ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 244 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 245 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 246 SOUTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AMERICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 254 ARGENTINA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 ARGENTINA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 257 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 258 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 259 ARGENTINA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 260 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 261 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 262 BRAZIL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 BRAZIL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 264 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 265 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 266 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 267 BRAZIL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 268 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 269 REST OF SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 270 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 271 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 272 MIDDLE EAST AND AFRICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 MIDDLE EAST AND AFRICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 275 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 276 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 277 MIDDLE EAST AND AFRICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 278 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 279 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 280 SOUTH AFRICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 SOUTH AFRICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 283 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 284 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 285 SOUTH AFRICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 286 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 287 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 288 EGYPT PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 289 EGYPT ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 291 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 292 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 293 EGYPT HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 294 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 295 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 296 SAUDI ARABIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 SAUDI ARABIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 298 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 299 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 300 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 301 SAUDI ARABIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 302 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 303 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 304 U.A.E. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 305 U.A.E. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 306 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 307 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 308 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 309 U.A.E. HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 310 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 311 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 312 ISRAEL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 313 ISRAEL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 314 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 315 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 316 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 317 ISRAEL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 318 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 319 REST OF MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
Liste des figures
FIGURE 1 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SEGMENTATION
FIGURE 2 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: END USER COVERAGE GRID
FIGURE 8 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SEGMENTATION
FIGURE 10 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: STRATEGIC DECISIONS
FIGURE 11 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SEGMENTATION TWO SEGMENTS COMPRISE
FIGURE 12 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: EXECUTIVE SUMMARY
FIGURE 13 RISING INCIDENCES OF IRON DEFICIENCY ANEMIA ARE DRIVING THE GROWTH OF THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET FROM 2024 TO 2031
FIGURE 14 THE THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET IN 2024 AND 2031
FIGURE 15 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR IRON-DEFICIENCY ANEMIA THERAPY MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 17 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET
FIGURE 18 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, 2023
FIGURE 19 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, 2024-2031 (USD MILLION)
FIGURE 20 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, CAGR (2024-2031)
FIGURE 21 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, LIFELINE CURVE
FIGURE 22 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, 2023
FIGURE 23 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, 2024-2031 (USD MILLION)
FIGURE 24 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, CAGR (2024-2031)
FIGURE 25 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 26 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, 2023
FIGURE 27 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, 2024-2031 (USD MILLION)
FIGURE 28 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, CAGR (2024-2031)
FIGURE 29 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, LIFELINE CURVE
FIGURE 30 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, 2023
FIGURE 31 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 32 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, CAGR (2024-2031)
FIGURE 33 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 35 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 36 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 37 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SNAPSHOT (2023)
FIGURE 39 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 40 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 41 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 42 ASIA - PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
